KRAS and non-small cell lung carcinoma: A separate targeted sequencing study in 47 NSCLC patients treated with anti-PD1 inhibitors found that patients with KRAS mutant tumors have a longer progression-free survival (PFS) and overall survival (OS) than KRAS wild-type patients (hazard ratio [HR] = 0.48, p  =  0.04)56.